# Deerfield Management Company, L.P. 13F Q2 2026: $9.6 billion

Deerfield Management Company, L.P. reported $9.6 billion in 13F securities across 82 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Nuvalent Inc at $2.1 billion, 22.2% of the reported value. Since Q1 2026 it opened 13 new positions and exited 13.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $9,586,027,944
- Positions: 82
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1009258
- Form 13F file number: 028-05366
- Business address: 345 Park Avenue South, 12th Floor, New York, NY 10010
- SEC filing: [0001213900-26-089991](https://www.sec.gov/Archives/edgar/data/1009258/000121390026089991/0001213900-26-089991-index.htm)

## Top 25 holdings by value

The largest of 82 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Nuvalent Inc](https://specstream.ai/data/institutional-holders/nuvalent-inc-670703107) | COM | 17,248,450 | $2.13 billion | No change |
| Brookdale Sr Living Inc | NOTE 3.500%10/1 (principal) | 306,885,000 | $585.7 million | No change |
| [Revolution Medicines Inc](https://specstream.ai/data/institutional-holders/revolution-medicines-inc-76155x100) | COM | 2,392,000 | $448 million | +95,000 |
| [Praxis Precision Medicines I](https://specstream.ai/data/institutional-holders/praxis-precision-medicines-i-74006w207) | COM NEW | 963,351 | $322.5 million | No change |
| [Viatris Inc](https://specstream.ai/data/institutional-holders/viatris-inc-92556v106) | COM | 20,206,170 | $320.9 million | No change |
| [Centene Corp Del](https://specstream.ai/data/institutional-holders/centene-corp-del-15135b101) | COM | 4,901,000 | $314.6 million | -1,016,091 |
| [Revolution Medicines Inc](https://specstream.ai/data/institutional-holders/revolution-medicines-inc-76155xaa8) | NOTE 0.500% 5/0 (principal) | 200,000,000 | $251.7 million | New |
| [United Therapeutics Corp Del](https://specstream.ai/data/institutional-holders/united-therapeutics-corp-del-91307c102) | COM | 457,000 | $247.6 million | No change |
| [Arrowhead Pharmaceuticals in](https://specstream.ai/data/institutional-holders/arrowhead-pharmaceuticals-in-04280aac4) | NOTE 1/1 (principal) | 200,000,000 | $240.5 million | No change |
| [Legend Biotech Corp](https://specstream.ai/data/institutional-holders/legend-biotech-corp-52490g102) | SPONSORED ADS | 8,137,638 | $235 million | +450,000 |
| [Cogent Biosciences Inc](https://specstream.ai/data/institutional-holders/cogent-biosciences-inc-19240q201) | COM | 5,006,104 | $193.7 million | -4,037,799 |
| [Genmab A/S](https://specstream.ai/data/institutional-holders/genmab-a-s-372303206) | SPONSORED ADS | 6,865,000 | $188.6 million | +4,403,000 |
| [Brookdale Sr Living Inc](https://specstream.ai/data/institutional-holders/brookdale-sr-living-inc-112463104) | COM | 11,637,032 | $187.2 million | No change |
| [Vera Therapeutics Inc](https://specstream.ai/data/institutional-holders/vera-therapeutics-inc-92337r101) | CL A | 3,916,400 | $168.1 million | +194,300 |
| [Ionis Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/ionis-pharmaceuticals-inc-462222100) | COM | 1,979,669 | $157 million | No change |
| [Celcuity Inc](https://specstream.ai/data/institutional-holders/celcuity-inc-15102k100) | COM | 1,451,014 | $151.8 million | -262,986 |
| [Biocryst Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/biocryst-pharmaceuticals-inc-09058v103) | COM | 15,096,403 | $151 million | +58,403 |
| [Newamsterdam Pharma Company](https://specstream.ai/data/institutional-holders/newamsterdam-pharma-company-n62509109) | ORDINARY SHARES | 4,264,789 | $144.5 million | No change |
| [Acadia Healthcare Company in](https://specstream.ai/data/institutional-holders/acadia-healthcare-company-in-00404a109) | COM | 4,520,000 | $133.5 million | No change |
| [Tango Therapeutics Inc](https://specstream.ai/data/institutional-holders/tango-therapeutics-inc-87583x109) | COM | 4,190,611 | $131 million | +43,798 |
| [Adapthealth Corp](https://specstream.ai/data/institutional-holders/adapthealth-corp-00653q102) | COMMON STOCK | 11,477,730 | $119.6 million | No change |
| [Pharvaris N V](https://specstream.ai/data/institutional-holders/pharvaris-n-v-n69605108) | COM | 3,376,042 | $116.7 million | +250,000 |
| [Celcuity Inc](https://specstream.ai/data/institutional-holders/celcuity-inc-15102kab6) | NOTE 0.250% 8/0 (principal) | 100,000,000 | $113.8 million | New |
| [Arrowhead Pharmaceuticals in](https://specstream.ai/data/institutional-holders/arrowhead-pharmaceuticals-in-04280a100) | COM | 1,389,055 | $113.2 million | -184,242 |
| [Dianthus Therapeutics Inc](https://specstream.ai/data/institutional-holders/dianthus-therapeutics-inc-252828108) | COM | 1,125,313 | $109.7 million | +105,500 |

## New positions in Q2 2026

13 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Revolution Medicines Inc](https://specstream.ai/data/institutional-holders/revolution-medicines-inc-76155xaa8) | NOTE 0.500% 5/0 (principal) | 200,000,000 | $251.7 million |
| [Celcuity Inc](https://specstream.ai/data/institutional-holders/celcuity-inc-15102kab6) | NOTE 0.250% 8/0 (principal) | 100,000,000 | $113.8 million |
| [Mineralys Therapeutics Inc](https://specstream.ai/data/institutional-holders/mineralys-therapeutics-inc-603170101) | COM | 3,958,000 | $106.8 million |
| [Boston Scientific Corp](https://specstream.ai/data/institutional-holders/boston-scientific-corp-101137107) | COM | 1,315,000 | $56.1 million |
| [Parabilis Medicines Inc](https://specstream.ai/data/institutional-holders/parabilis-medicines-inc-698955101) | COM | 1,880,704 | $51.5 million |
| [Avalyn Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/avalyn-pharmaceuticals-inc-05348y105) | COM SHS | 731,000 | $24.1 million |
| [Odyssey Therapeutics Inc](https://specstream.ai/data/institutional-holders/odyssey-therapeutics-inc-67613t104) | COMMON STOCK | 1,046,139 | $19.6 million |
| [Alamar Biosciences Inc](https://specstream.ai/data/institutional-holders/alamar-biosciences-inc-010911105) | COMMON STOCK | 600,000 | $16.3 million |
| [Chemed Corp New](https://specstream.ai/data/institutional-holders/chemed-corp-new-16359r103) | COM | 30,000 | $14 million |
| [Adagene Inc](https://specstream.ai/data/institutional-holders/adagene-inc-005329107) | ADS | 2,666,666 | $11.2 million |
| [Hemab Therapeutics Hldgs Inc](https://specstream.ai/data/institutional-holders/hemab-therapeutics-hldgs-inc-423494103) | COM SHS | 275,000 | $10.1 million |
| [Mobia Med Inc](https://specstream.ai/data/institutional-holders/mobia-med-inc-60705v103) | COMMON STOCK | 670,752 | $9 million |
| [Mirum Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/mirum-pharmaceuticals-inc-604749101) | COM | 6,027 | $705,581 |

## Positions exited in Q2 2026

13 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Mirum Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/mirum-pharmaceuticals-inc-604749ab7) | NOTE 4.000% 5/0 (principal) | 70,000,000 | $209.4 million |
| [Catalyst Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/catalyst-pharmaceuticals-inc-14888u101) | COM | 3,943,600 | $97.6 million |
| [Neurocrine Biosciences Inc](https://specstream.ai/data/institutional-holders/neurocrine-biosciences-inc-64125c109) | COM | 610,000 | $80.4 million |
| Day One Biopharmaceuticals I | COM | 3,723,131 | $79.8 million |
| Enhabit Inc | COM | 4,747,746 | $66.9 million |
| [Kymera Therapeutics Inc](https://specstream.ai/data/institutional-holders/kymera-therapeutics-inc-501575104) | COM | 561,170 | $46.7 million |
| [Compass Therapeutics Inc](https://specstream.ai/data/institutional-holders/compass-therapeutics-inc-20454b104) | COM | 3,606,000 | $19.1 million |
| [Taysha Gene Therapies Inc](https://specstream.ai/data/institutional-holders/taysha-gene-therapies-inc-877619106) | COM SHS | 2,722,165 | $12.2 million |
| [Cullinan Therapeutics Inc](https://specstream.ai/data/institutional-holders/cullinan-therapeutics-inc-230031106) | COM | 386,169 | $5.5 million |
| Biomx Inc | COM NEW | 131,272 | $492,795 |
| [Veradermics Inc](https://specstream.ai/data/institutional-holders/veradermics-inc-922967104) | COMMON STOCK | 5,000 | $315,750 |
| Quantum Si Inc | \*W EXP 06/10/202 | 333,333 | $36,200 |
| [Myriad Genetics Inc](https://specstream.ai/data/institutional-holders/myriad-genetics-inc-62855j104) | COM | 505 | $2,273 |

## Also on SpecStream

- [Deerfield Management Company, L.P. Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1009258/000121390026089991/0001213900-26-089991-index.htm)
- [Largest 13F filers in New York](https://specstream.ai/data/institutional-holdings/state/new-york)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in New York, New York

- [Surgical supply companies in New York, New York](https://specstream.ai/data/businesses/surgical-supply-companies/new-york-new-york-united-states)
- [Telecommunications services in New York, New York](https://specstream.ai/data/businesses/telecommunications-services/new-york-new-york-united-states)
- [Uniform stores in New York, New York](https://specstream.ai/data/businesses/uniform-stores/new-york-new-york-united-states)
- [Waste collection companies in New York, New York](https://specstream.ai/data/businesses/waste-collection-companies/new-york-new-york-united-states)
- [Adult education centers in New York, New York](https://specstream.ai/data/businesses/adult-education-centers/new-york-new-york-united-states)
- [Appraisers in New York, New York](https://specstream.ai/data/businesses/appraisers/new-york-new-york-united-states)
